The likelihood of being dispensed selected cardiovascular medicines increased with each successive time period (from Year 2 to Year 5 following breast cancer diagnosis) and varied by types of medication classes ranging from 3% for agents acting on renin-angiotensin system (OR 1.03; 95%CI = 1.01–1.05), 6% for lipid-modifying agents (OR 1.06; 95%CI = 1.03–1.08), 8% for beta-blockers (OR 1.08; 95%CI = 1.04–1.11), through to 12% for cardiac therapy (OR 1.12; 95%CI = 1.06–1.18). This evidence concerns the gene REN and breast carcinoma.